Review Article
Progress in Rectal Cancer Treatment
Table 3
Neoadjuvant chemotherapy followed by chemoradiation in locally advanced rectal cancer.
| | Study Regimen | | int(w) | SPS | pCR | DFS | OS | | Neoadjuvant | CRT | Adjuvant |
| |
Chau et al. [100] | 5-FU, MMC (7) | 50.4 Gy with 5-FU | 5-FU, MMC (7) | 36 | 6 | 56% | 3% | 1 y: 72.1% | 2 y: 70.3% | | EXPERT [101] | CAP (1000), OX (130)
| 54 Gy with CAP (825)
| CAP (1250)
| 105
| 6
| 63%
| 20%
| 3 y: 68%
| 3 y: 83%
| |
GCR3 [94] | — | 50.4 Gy with CAP (825) | CAP (2000), OX (130) | 52 | 5-6 | — | 13% | 1.5 y: 82% | 1.5 y: 89% | | CAP (2000), OX (130)
| 50.4 Gy with CAP (825)
| —
| 56
| 5-6
| —
| 14%
| 1.5 y: 76%
| 1.5 y: 91%
| |
BGDO [95] | — | 45 Gy with 5-FU CIV | — | 29 | 6–8 | 67% | 27% | — | — | | 5-FU, OX (100)
| 45 Gy with 5-FU CIV
| —
| 28
| 6–8
| 100%
| 25%
| —
| —
| |
Schou et al. [102] | CAP(2000), OX (130) | 54 Gy + CAP (1650) | None | 84 | 6 | — | 25% | 5 y: 63% | 5 y: 67% | | AVACROSS [96] | CAP (1000), OX (130), bev | 45 Gy + CAP (825) + bev | CAP + OX | 47 | 6–8 | 60% | 36% | — | — | |
Dipetrillo et al. [83] | 5-FU, OX (85), bev
| 50.4 Gy + OX (50) + bev
| 5-FU + OX + bev
| 26
| 4–8
| 76%
| 20%
| 4 y: 65%
| 4 y: 96%
| |
EXPERT-C [78] | CAP (1700), OX (130) | 50.4 Gy + CAP (1650) | CAP + OX | 81 | 4–6 | 73% | 15% | HR: 0.3–2.16 | HR: 0.07–0.99 | | CAP (1700), OX (130), cet | 50.4 Gy + CAP (1650) + cet | CAP + OX + cet | 84 | 4–6 | 73% | 14% | | |
|
|
CAP: capecitabine; MMC: mitomycin C; OX: oxaliplatin; cet: cetuximab; bev: bevacizumab; RT: radiotherapy; pCR: pathological complete response; SPS: sphincter preserving surgery; OS: overall survival; DFS: disease free survival; int: interval in weeks.
|
